| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief R&D Officer
1 company
Zalevsky Jonathan is a Chief R&D Officer at NEKTAR THERAPEUTICS. Recent SEC Form 4 filings include 0 buys and 10 sells.
Estimated insider holdings value: $2.1M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 16, 2021 | NKTR Nektar Therapeutics | Chief R&D Officer | Sell | 20,869 | $13.16 | $274,636.04 | -8.3% | -18.3% | -73.5% | |
| Aug 16, 2021 | NKTR Nektar Therapeutics | Chief R&D Officer | Sell | 7,662 | $13.83 | $105,965.46 | -3.5% | -3.1% | -66.0% | |
| May 17, 2021 | NKTR Nektar Therapeutics | Chief R&D Officer | Sell | 31,111 | $18.30 | $569,331.30 | -11.7% | -24.3% | -78.3% | |
| Feb 16, 2021 | NKTR Nektar Therapeutics | Chief R&D Officer | Sell | 24,141 | $22.37 | $540,034.17 | -8.3% | - | - | |
| Nov 23, 2020 | NKTR Nektar Therapeutics | Chief R&D Officer | Sell | 16,380 | $16.40 | $268,632.00 | -6.1% | - | - | |
| Nov 16, 2020 | NKTR Nektar Therapeutics | Chief R&D Officer | Sell | 29,618 | $16.93 | $501,432.74 | -10.0% | - | - | |
| Aug 17, 2020 | NKTR Nektar Therapeutics | Chief R&D Officer | Sell | 26,200 | $19.67 | $515,354.00 | -8.1% | - | - | |
| May 18, 2020 | NKTR Nektar Therapeutics | Chief R&D Officer | Sell | 4,558 | $22.51 | $102,600.58 | -1.4% | - | - | |
| Feb 18, 2020 | NKTR Nektar Therapeutics | Chief R&D Officer | Sell | 4,774 | $22.35 | $106,698.90 | -1.4% | - | - | |
| Nov 18, 2019 | NKTR Nektar Therapeutics | Chief R&D Officer | Sell | 3,960 | $17.97 | $71,161.20 | -1.3% | - | - |